v3.22.2.2
Condensed Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Operating activities    
Net loss $ (16,053) $ (50,380)
Adjustments to reconcile net loss to net cash used in operating activities:    
Stock-based compensation 1,383 1,435
Depreciation 3 3
Fair value change in warrant liabilities 0 33,829
Non-cash share settlement with investors 0 1,614
Receipts of investments related to license agreement 0 (289)
Unrealized loss (gain) from short-term investments 118 (94)
Change in assets and liabilities:    
Prepaid expenses and other assets 709 709
Accounts payable (125) 216
Accrued and other liabilities (512) (767)
Net cash used in operating activities (14,477) (13,724)
Investing activities    
Net cash used in investing activities 0 0
Financing activities    
Proceeds from issuance of common stock - registered direct offering 0 15,000
Proceeds from issuance of common stock - at-the-market program 4,428 5,806
Issuance costs (119) (1,317)
Payments in connection with short-term loan (538) 0
Exercise of stock options and Series B warrants 27 86
Net cash provided by financing activities 3,798 19,575
Net (decrease) increase in cash and cash equivalents (10,679) 5,851
Cash and cash equivalents at beginning of period 24,534 16,399
Cash and cash equivalents at end of period 13,855 22,250
Supplemental disclosure of cash flow information:    
Cash paid for income taxes 0 0
Cash paid for interest 9 0
Supplemental non-cash financing transactions:    
Non-cash reclassification of Series A warrant liability to equity 0 61,793
Unpaid issuance and deferred offering costs $ 11 $ 4

Source